Baseline Glucose-to-Lymphocyte Ratio Predicts Nivolumab Outcomes in Advanced Non-Small Cell Lung Cancer - A Multicenter Retrospective Study
Favorite
Share
More Options
11

Open in WPS to view all 11 pages
This document is user-generated content (UGC). WPS Office is not responsible for its accuracy or copyright. If you believe this content violates your rights, please use the button.
